Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.
TLDR
This review focuses on summarizing PD-L1 regulation and its potential roles in regulating antitumor immune response, with purpose to optimize anti-PD-1/PD- L1 therapies, benefiting a wider cancer patient population.About:
This article is published in Trends in Biochemical Sciences.The article was published on 2018-12-01 and is currently open access. It has received 132 citations till now. The article focuses on the topics: Cancer immunotherapy & Cancer.read more
Citations
More filters
Journal ArticleDOI
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Andrew M. Davis,Vaibhav G. Patel +1 more
TL;DR: The findings indicate that PD-L1 expression as a predictive biomarker has limitations and that the decision to pursue testing must be carefully implemented for clinical decision-making.
Journal ArticleDOI
Mechanisms Controlling PD-L1 Expression in Cancer
TL;DR: Current knowledge of PD-L1 regulatory mechanisms at the transcriptional, posttranscriptional,post-translational, and extracellular levels are provided, and the implications of these findings in cancer diagnosis and immunotherapy are discussed.
Journal ArticleDOI
Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy
Yang Gao,Yang Gao,Naoe Taira Nihira,Naoe Taira Nihira,Naoe Taira Nihira,Xia Bu,Chen Chu,Jinfang Zhang,Aleksandra Kolodziejczyk,Yizeng Fan,Yizeng Fan,Ngai Ting Chan,Leina Ma,Jing Liu,Dong Wang,Xiaoming Dai,Huadong Liu,Masaya Ono,Akira Nakanishi,Hiroyuki Inuzuka,Brian J. North,Yu Han Huang,Samanta Sharma,Yan Geng,Wei Xu,X. Shirley Liu,Lei Li,Yoshio Miki,Piotr Sicinski,Gordon J. Freeman,Wenyi Wei +30 more
TL;DR: It is reported that PD-L1 translocates from the plasma membrane into the nucleus through interactions with components of the endocytosis and nucleocytoplasmic transport pathways, regulated by p300-mediated acetylation and HDAC2-dependent deacetylation of PD- L1.
Journal ArticleDOI
Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles.
Zhaohan Wei,Xiaoqiong Zhang,Tuying Yong,Nana Bie,Guiting Zhan,Xin Li,Qingle Liang,Jianye Li,Jingjing Yu,Gang Huang,Yuchen Yan,Zelong Zhang,Bixiang Zhang,Lu Gan,Bo Huang,Xiangliang Yang +15 more
TL;DR: In this article, mannose-modified macrophage-derived microparticles (Man-MPs) loading metformin (Met@ManMPs), are developed to efficiently target to M2-like TAMs to repolarize into M1-like phenotype.
Journal ArticleDOI
Natural products and their derivatives: Promising modulators of tumor immunotherapy.
TL;DR: A deep generalization, analysis, and summarization of the previous achievements, recent progress, and the bottlenecks in the development of natural products as tumor immunotherapy are performed.
References
More filters
Journal ArticleDOI
Hallmarks of cancer: the next generation.
TL;DR: Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.
Journal ArticleDOI
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
TL;DR: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma.
Journal ArticleDOI
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
Julie R. Brahmer,Karen L. Reckamp,Paul Baas,Lucio Crinò,Wilfried Eberhardt,Elena Poddubskaya,Scott J. Antonia,Adam Pluzanski,Everett E. Vokes,Esther Holgado,David M. Waterhouse,Neal Ready,Justin F. Gainor,Osvaldo Arén Frontera,Libor Havel,Martin Steins,Marina Chiara Garassino,Joachim G.J.V. Aerts,Manuel Domine,Luis Paz-Ares,Martin Reck,Christine Baudelet,Christopher T. Harbison,Brian Lestini,David R. Spigel +24 more
TL;DR: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level.
Journal ArticleDOI
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Brandon Luber,Nilofer S. Azad,Daniel A. Laheru,Barbara A. Biedrzycki,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Steven M. Duffy,Richard M. Goldberg,Richard M. Goldberg,Albert de la Chapelle,Albert de la Chapelle,Minori Koshiji,Feriyl Bhaijee,Thomas Huebner,Ralph H. Hruban,Laura D. Wood,Nathan Cuka,Drew M. Pardoll,Nickolas Papadopoulos,Kenneth W. Kinzler,Shibin Zhou,Toby C. Cornish,Janis M. Taube,Robert A. Anders,James R. Eshleman,Bert Vogelstein,Luis A. Diaz +36 more
TL;DR: This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab, and high somatic mutation loads were associated with prolonged progression-free survival.
Journal ArticleDOI
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi,Naiyer A. Rizvi,Matthew D. Hellmann,Matthew D. Hellmann,Alexandra Snyder,Alexandra Snyder,Pia Kvistborg,Vladimir Makarov,Jonathan J. Havel,William Lee,Jianda Yuan,Phillip Wong,Teresa S. Ho,Martin L. Miller,Natasha Rekhtman,Andre L. Moreira,Fawzia Ibrahim,Cameron Bruggeman,Billel Gasmi,Roberta Zappasodi,Yuka Maeda,Chris Sander,Edward B. Garon,Taha Merghoub,Jedd D. Wolchok,Jedd D. Wolchok,Ton N. Schumacher,Timothy A. Chan,Timothy A. Chan +28 more
TL;DR: Treatment efficacy was associated with a higher number of mutations in the tumors, and a tumor-specific T cell response paralleled tumor regression in one patient, suggesting that the genomic landscape of lung cancers shapes response to anti–PD-1 therapy.
Related Papers (5)
Regulation and Function of the PD-L1 Checkpoint
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Chia Wei Li,Seung Oe Lim,Weiya Xia,Heng Huan Lee,Li Chuan Chan,Li Chuan Chan,Chu Wei Kuo,Kay-Hooi Khoo,Shih Shin Chang,Jong Ho Cha,Taewan Kim,Jennifer L. Hsu,Jennifer L. Hsu,Jennifer L. Hsu,Yun Wu,Jung Mao Hsu,Hirohito Yamaguchi,Qingqing Ding,Yan Wang,Jun Yao,Cheng Chung Lee,Hsing Ju Wu,Aysegul A. Sahin,James P. Allison,Dihua Yu,Gabriel N. Hortobagyi,Mien Chie Hung +26 more
Deubiquitination and Stabilization of PD-L1 by CSN5
Seung Oe Lim,Chia Wei Li,Weiya Xia,Jong Ho Cha,Li Chuan Chan,Yun Wu,Shih Shin Chang,Shih Shin Chang,Wan Chi Lin,Jung Mao Hsu,Yi Hsin Hsu,Taewan Kim,Wei Chao Chang,Jennifer L. Hsu,Hirohito Yamaguchi,Qingqing Ding,Yan Wang,Yi Yang,Chung-Hsuan Chen,Aysegul A. Sahin,Dihua Yu,Dihua Yu,Gabriel N. Hortobagyi,Mien Chie Hung +23 more
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.
Jong Ho Cha,Wen Hao Yang,Weiya Xia,Yongkun Wei,Li Chuan Chan,Seung Oe Lim,Chia Wei Li,Taewan Kim,Shih Shin Chang,Heng Huan Lee,Jennifer L. Hsu,Hung Ling Wang,Chu Wei Kuo,Wei Chao Chang,Sirwan Hadad,Colin A. Purdie,Aaron McCoy,Shirong Cai,Yizheng Tu,Jennifer K. Litton,Elizabeth A. Mittendorf,Stacy L. Moulder,William Fraser Symmans,Alastair M. Thompson,Helen Piwnica-Worms,Chung-Hsuan Chen,Kay-Hooi Khoo,Mien Chie Hung +27 more